»Ë»Ñ Æ÷·³

Á¦¾à ¹ÙÀÌ¿À µ¥Àϸ® ´º½º

[ÇÑÅõÁõ±Ç ÁøÈ«±¹] Á¦¾à/¹ÙÀÌ¿À µ¥Àϸ® ´º½º

¾È³çÇϼ¼¿ä ÇÑÅõÁõ±Ç Á¦¾à¹ÙÀÌ¿À ÁøÈ«±¹ÀÔ´Ï´Ù.


¢º️ÀüÀÏ ¹Ì±¹ ÁÖ¿ä À妽º

* ´Ù¿ì -0.3% S&P Á¦¾à +1.1% ³ª½º´Ú ¹ÙÀÌ¿À +0.4%


¢º️ÇØ¿Ü Peer ÀüÀÏ ÁÖ°¡

* ¼¿Æ®¸®¿Â °ü·Ã: Pfizer -0.5% J&J +0.7% Teva +4.2% Mylan +3.1%
* »ï¼º¹ÙÀÌ¿À °ü·Ã: Lonza -0.6% Merck -0.3% Roche -0.1% Amgen -0.1% Biogen -1.1%
* Çѹ̾àÇ° °ü·Ã: Sanofi -0.2% Spectrum +1.3%
* º¸Å彺: Allergan -0.6% Revance Therapeutic -1.3% Evolus -0.1%
* ±âŸ: Gilead Science +0.4% Regeneron +1.4% Abbvie -0.4% Celgene +0.1% Eli Lilly +0.3% CSL +0.2%


¢º️±¹³» À̽´

* »ï¼º¹ÙÀÌ¿À, Ú¸¼­ È޹̶ó ¹ÙÀÌ¿À½Ã¹Ð·¯ ÆǸÅÇã°¡

* FDA Çã°¡ ¹ÙÀÌ¿À½Ã¹Ð·¯ 23°³ Áß 7°³ '¸ÞÀ̵åÀÎÄÚ¸®¾Æ'

* ·Î½´ Ƽ½ëÆ®¸¯, ±¹³» óÀ½ 'PD-L1 °ü°è¾øÀÌ' ±Þ¿©Àû¿ë

* °ËÂû, 'Àκ¸»ç »çÅÂ' ÄÚ¿À·Õ º»»ç ¾Ð¼ö¼ö»ö

* Áö¿¤ÆÊÅØ, ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ÀÓ»ó 1»ó IND ½ÂÀÎ

* ½ÅdzÁ¦¾à, Ú¸ USAID¿Í Ç׸»¶ó¸®¾Æ Ä¡·áÁ¦ ¡®ÇǶó¸Æ½º¡¯ Àå±â°ø±ÞÇÕÀÇ


¢º️ÇØ¿Ü À̽´

* ºÒ¸éÁõ¡¤¿ì¿ïÁõ Ä¡·á 'µðÁöÅнžà'?.."Æä¾î, Ú¸ Çã°¡ ½Åû"

* ±æ¸®¾îµå, Àå±âÁö¼ÓÇü AIDS ÁÖ»çÁ¦ °³¹ß Á¦ÈÞ

* Lonza expanding ADC production as pharma business thrives 

* Biogen leads the way in renewed amyotrophic lateral sclerosis push

0
ÃßõÇϱ⠴ٸ¥ÀÇ°ß 0
|
°øÀ¯¹öÆ°
  • ¾Ë¸² ¿å¼³, »óó ÁÙ ¼ö ÀÖ´Â ¾ÇÇÃÀº »ï°¡ÁÖ¼¼¿ä.
©¹æ »çÁø  
¡â ÀÌÀü±Û¡ä ´ÙÀ½±Û